Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of tunlametinib plus vemurafenib in BRAF V600E-mutant metastatic colorectal cancer
CTR20232218Phase 3Active
- Sponsor
- Shanghai KeChow Pharmaceuticals
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tunlametinib, vemurafenib in colorectal cancer (CRC), sponsored by Shanghai KeChow Pharmaceuticals. Started Oct 2023; status: active.
02
Drugs
tunlametinibvemurafenib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20232218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232218.